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Summary Severe methotrexate (MTX) toxicity is a proven complication of associations of MTX and
non-steroidal anti-inflammatory drugs (NSAIDs). This study investigated the interaction between MTX (50 or
100 mg kg-') and ketoprofen (KP) (3 mg kg-' day-', pretreatment for 8 days) in the rabbit. The drug
association induced a reversible increase in blood urea and creatinine. The severity degree of renal dysfunction
was significantly related to the MTX dose; it was not modified by prolonged exposure to KP after MTX
administration. The biological markers of haematopoietic and hepatic functions were unchanged. Pretreatment
by KP induced a marked reduction (70%) in the urinary excretion of the prostaglandin 6-keto-PGF,m. MTX
dose-related alterations in MTX pharmacokinetics were also observed with the drug association: at a MTX
dose of 100 mg kg- , the presence of KP significantly reduced the total body clearance, the renal clearance and
the fraction of MTX eliminated in urine as compared to controls. An appreciable reduction in the plasma
binding of MTX was also noted in vivo when KP was associated. This experimental study confirms the
existence of an interaction between MTX and KP and demonstrates its renal origin.
An unexpected, life-threatening toxicity was recently
observed in our institution when high dose methotrexate
(MTX) was given concurrently with the non-steroidal anti-
inflammatory drug (NSAID) ketoprofen (KP) (Thyss et al.,
1986). Simultaneous administration of the two drugs resulted
in prolonged and marked enhancement of MTX serum levels.
Since then, additional evidence of severe MTX toxicity has
been reported when other NSAIDs are given with high dose
MTX (Maiche, 1986) and even with low dose MTX (Singh et
al., 1986; Daly et al., 1986). The fact that indomethacin
(Maiche, 1986), naproxen (Singh et al., 1986) and azapro-
pazone (Daly et al., 1986) have also been implicated supports
our initial conclusions that the high risk of an association
between MTX and KP should be extended to include other
NSAIDs. A more recent study (Ahern et al., 1988) analysed
the blood kinetics of low dose oral MTX in rheumatoid
arthritis when NSAIDs were given conjointly. The authors
concluded that despite apparent interaction in individual
patients, mean kinetic variables did not differ significantly
with and without NSAIDs therapy. This clearly raises the
question of the importance of the MTX dose in the intensity
of the drug interaction. Another major question is the origin
of the interaction. Post-treatment serum creatinine levels
were raised in 75% of our cases (Thyss et al., 1986), but it
was hard to determine whether KP itself or overexposure to
MTX was responsible for the renal dysfunction. As MTX
(Shen & Azarnoff, 1978) and KP (Verbeek et al., 1983) are
bound to plasma proteins, possible displacement of MTX
from its binding site by KP is another hypothesis. These
various observations motivated the present investigation of
the interaction between MTX and KP in a laboratory animal
to identify its major determinants. The rabbit was selected
(Sasaki et al., 1983) because it reproduces the extensive
metabolism of MTX into 7-OH-MTX described in patients
(Breithaupt & Kuenzlen, 1982; Milano et al., 1983).
The effects of the MTX dose and duration of KP exposure
were analysed. MTX and 7-OH-MTX pharmacokinetics were
evaluated and the biological parameters linked to hemato-
poietic, hepatic and renal functions were monitored. Renal
excretion of a representative prostaglandin (6-keto-PGFIm)
was also measured in the different experimental situations.
Material and methods
Chemicals andequipment
MTX chemical purity was 96.1% (Batch 37 859 - Lederle) by
HPLC analysis. MTX powder for injection 500 mg (R Bel-
Ion) in vials containing MTX sodium equivalent to MTX
500 mg, given at 50 and 100 mg kg- '.
7-OH-MTX was prepared in our laboratory according to a
method previously published (Jacobs et al., 1976). Briefly,
MTX was incubated on rabbit liver homogenate purified in
aldehyde oxidase activity. Total recovery was 15% (10 mg of
7-OH-MTX recovered for 75 mg of MTX incubated). The
purity of the 7-OH-MTX (96%) was checked by HPLC and
by UV and IR spectral analysis (Jacobs et al., 1976) (valency
vibration of the -OH radical absorbing at 3,460cm-').
A KP preparation for i.v. injections (Profenid i.m. 100 mg
Specia-Rhone Poulenc) was given at 3 mg kg-'.
A calcium folinate preparation for i.v. injections (Leder-
foline 50 mg, Lederle) was diluted five times by NaCI 0.9%
and given at 0.5 mgkg-'.
Cartridges for ultrafiltration were Centrifree (Amicon,
Grace). Cartridges for solid extraction before HPLC analysis
were SepPak C18 (Millipore Waters).
A commercial RIA (1251) kit was used for measurement of
the prostaglandin 6-Keto-PGF,r. (Amersham code RPA 515).
The HPLC system included a 6000 A pump and an auto-
matic sample injector (WISP, Millipore Waters), an UV
detector (Spectroflow 783 - Kratos) and an integrator cal-
culator 3390 A (Hewlett Packard).
For biochemistry we used: a Coulter Counter, model S-
Plus II for complete blood count; a Centrifichem system 500
(Union Carbide) for measurement of plasma transaminases
and bilirubin; an Astra (Beckman) for urea, creatinine and
plasma electrolytes; and a TDX analyser (ABBOTT) for
measurement of MTX (free fraction) by fluorescent polarisa-
tion immunoassay.
Radioactivity measurement was by Packard Tri-card 460
for beta emissions and LKB 1260 Multigamma for gamma
emissions.
Animals and treatment
Female New Zealand rabbits (2.5-3.5 kg) delivered by
Elevage Scientifique des Dombes (Chatillon/Chalaronne,
France) were placed in individual cages; they were left to
acclimate for 1 week in the animal house. They received food
(type 112: UAR, Epinay) and drink ad libitum. Thirty
animals were treated by MTX at i.v. bolus doses of 50 and
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100 mg kg-' (15 animals per dose). Six controls received KP
alone and/or saline. The animals were treated i.m. with KP
3 mg kg-' day-' (or, for controls, saline) for 8 days
(sequence A) or for 11 days (sequence B, KP being prolonged
3 days after MTX); they received MTX (50 or 100 mg kg-')
on day 8 and calcium folinate 0.5 mg kg-' day-' for 3 days
after MTX.
Biological samples
Blood was taken from the marginal vein of the ear (5 animals
per experimental condition). For plasma analysis of bio-
chemical parameters, 2 ml of blood was obtained at the
following times: the day before the beginning of pre-treat-
ment (day -8, where day 0 is the day of MTX administra-
tion); just before MTX administration, at day 0; after the
administration of MTX, and during 2 weeks on days 1, 2, 3,
6, 9 and 14. For the analysis of plasma MTX and 7-OH-
MTX, 2ml of blood was obtained at the following times
after the MTX i.v. bolus injection: 1, 2, 4, 6, 8, 12, 24, 36, 48
and 72 h. Complete blood counts were performed on blood
samples collected on EDTA at the same times as indicated
for the biological parameters.
Urine was collected for three different animals per experi-
mental condition. Animals were kept in metabolic cages
allowing separation of faeces and urine. Urines were cooled
to 0-4°C just after mictation, and were collected by 24 h
fractions in a temperature-controlled flask containing 1 ml of
thimerosal (0.5% in H20), an antiseptic, and niflumic acid
0.5% to inhibit prostaglandin synthetase. Before each new
urine collection, the cage was rinsed with H20 (50-75 ml);
this aqueous fraction was added to the fraction collected
previously. Before deep freezing at -20°C, the total volume
was measured, and 20 ml aliquots for 6-keto-PGFI, analysis
were stored in conical polypropylene tubes with screw tops;
the remaining urines was used for quantitation of MTX and
7-OH-MTX.
Pharmacological and biologicalparameters
MTX and 7-OH-MTX were measured simultaneously by
HPLC with UV detection (303 nm) after a solid phase pre-
analytical extraction (Collier et al., 1982). The HPLC separa-
tion was done in a column Lichrospher 100 RP-18, 250 x
4mm, 5 jAm (Merck) with an isocratic elution (1.3 ml min-)
by tetrabutyl ammonium sulphate (Pic A Low UV, Waters
Millipore) adjusted to pH 7.5 by H3PO4 and with 36%
methanol. The detection was done by spectrophotometry
(A= 303 nm, Kratos M 783). Distribution of the different
points between 5.5 x 10-8 M and 5.5 x 10-4 M gave a mean
recovery of 97 ± 1% for MTX and 77.5 ± 9% for 7-OH-
MTX. Standard curves were plotted between 20 nM and 2JAM
for MTX and between 50 nM and 2 JAM for 7-OH-MTX. The
external standard method was used. Responses (peak heights)
were linearly related to the respective concentrations of MTX
and its metabolite, with r = 0.99 for both compounds.
After thawing, the urine samples were alkalinised with a
small volume of 20 N NaOH to ensure the total redissolution
of any MTX and 7-OH-MTX that might precipitate during
freezing. After centrifugation of a 1 ml aliquot, 30-100p1 of
the supernatant were directly injected into the HPLC system.
Calibration curves were obtained from blank urine spiked
with known amounts of MTX and 7-OH-MTX (5.5 x 10-7 M
to 5.5 x 10-4 M). Due to the presence of interfering endo-
genous peaks in rabbit urines, a modified HPLC method was
used. Briefly, IL Bondapak phenyl columns, 10tiM (3.9 x
300 mm, Millipore Waters) were equipped with a CN guard
column (Millipore Waters). The mobile phase (flow rate of
2 mlmin-') was a mixture of sodium acetate buffer/CH3CN
(pH 4.4); the respective proportions for MTX and 7-OH-
MTX analysis were sodium acetate 0.1 M CH3CN 14% and
sodium acetate 0.2 M CH3CN 11%.
Blood samples collected 2 and 6 h after MTX administra-
tion were used to measure the free plasma MTX fraction for
rabbits treated by MTX only or by MTX plus KP. After
blood collection, tubes were immediately placed in a flask
containing water and ice (4C) and centrifuged at 1,500g,
10 min, 4C. An aliquot (250-500 p1l) of the resulting plasma
was then centrifuged in a Centrifree unit at 2,500g, 20min,
4°C. The ultrafiltrate was stored at -20°C until analysis of
MTX by fluorescent polarisation immunoassay. The value of
the cross reactivity with 7-OH-MTX was 1.5% (Evans et al.,
1986).
A complementary study of plasma binding has been per-
formed in vitro with plasma obtained from rabbits. There
were three different experimental conditions: MTX or 7-OH-
MTX incubated without KP (control); MTX or 7-OH-MTX
plus KP without pre-incubation of plasma with KP; and
MTX or 7-OH-MTX plus KP with a pre-incubation of
plasma with KP (2 h at 37°C, for simulation of the in vivo
conditions). The experimental conditions were as follows:
950jlA of plasma for rabbit; 25p1l of stock solution of MTX
(or 7-OH-MTX) giving a final concentration of 2 x 10-4 M
(this concentration compares well with the mean blood con-
centrations measured in rabbits 1 and 2 h after the adminis-
tration of MTX (100 mg kg-'); 25 p1 of a solution of KP
giving the respective final concentrations of 2 x 10-4 M, 2 x
10-M and 2 x 10-6 M (for rabbits treated by 3 mg kg-' a
mean blood concentration of 4 x 10- M has been described
(Populaire et al., 1973)). The plasma spiked with drugs was
incubated for 30 min at 37°C under agitation. It had been
previously checked that the steady state of MTX or 7-OH-
MTX (2 x 10-4 M) binding in plasma was reached after 30
min of incubation. At the end of the incubation the tubes
were immediately refrigerated at 4°C and treated by ultra-
filtration as described above. MTX and 7-OH-MTX were
analysed by HPLC as described above.
Haematopoietic function was assessed by the circulating
erythrocyte, white blood cell and platelet counts. Renal func-
tion was evaluated by the plasma levels of Na, K, Cl, urea,
creatinine. Hepatic function was checked by measurement of
plasma bilirubin, aspartate, and alanine transaminases.
Urinary prostaglandin 6-keto-PGFI,, was measured using
the appropriate RIA kit. Urines were extracted before ana-
lysis. The extraction step (Powell, 1982) was as follows: after
activation of the extraction cartridge by successive passages
of 5 ml methanol and 5 ml H20, 20 ml ofacidified urines (pH
3-4 with 8 M citric acid) were injected. This was followed by
the passage of 10 ml H20; the initial and aqueous eluate were
then discarded. Then, 10 ml ethanol 10% in H20 and 10 ml
of n-hexan were injected, and the resulting eluates were dis-
carded. Finally, elution by 10 ml of methyl formiate allowed
recovery of the prostanoid-containing fraction. This solution
was dried in a silicone-coated tube under a stream of nitro-
gen at exactly 30°C. The dried residue was redisolved in
200lil ethanol, followed by two times 0.9 ml phosphate
buffer, 0.05 M with 0.05% bovine serum albumin, pH 7.4.
This optimised process allowed recovery of 93.9% (± 9.2%,
n = 37) from a pure labelled standard of 6-keto-PGFI,
(Sigma). A radioactive tracer was added to the initial urines
to make sure the prostaglandin was not denatured during the
entire extraction process. This last step was done by HPLC
as follows (Peters et al., 1983): C18 HPLC column, 5 Lim
(4.6 x 250 mm, Beckman), UV detection at 200 nm, flow rate
1.5 ml min-' with a mobile phase composed of CH3 CN:33,
acetic acid 0.1% in H20: 67; final pH 4.1 adjusted with
NaOH 2N.
Pharmacokinetic analysis
For MTX, the concentration-time data were best fitted to a
two-exponential equation. For 7-OH-MTX, the concen-
tration-time data were best fitted to a three-exponential
equation after extravascular dosing without lag time. Cal-
culations were done using a pharmacokinetics program based
on least squares procedure with a weight as I/ly (Siphar-
Base, Simed, Creteil, France). The following pharmacokinetic
parameters were thus computed: half life for the elimination
phase= tl/2P; area under curve extrapolated to infinity with
the fitted model: AUC<,.,; total body clearance: Cl TB =738 A. PERRIN et al.
dose/AUC<,,; renal clearance = CLR = quantity excreted in
urine during 72 h (jAmol kg-') divided by AUCO0..
fu = fraction of the MTX dose excreted as unchanged drug
in urines, calculated as (Xu/mg)/total dose (mg) x 100 with
Xu = total volume of urines x MTX urine concentration.
Vdss = volume of distribution at the steady-state calcu-
lated as Cl TB x MRT (mean residence time) with MRT=
(A/a2) + (B/P2).
Statistical analysis
The t test for paired samples and the Mann-Whitney U test
were used for comparison of data.
Results
Biologicalparameters
Compared to controls (NaCl 0.9%), treatment by KP alone
or MTX alone (50 and 100 mg kg-', without pretreatment by
KP) did not modify the individual biological parameters
related to renal function. By contrast, increased blood urea
and creatinine levels were noted with the MTX-KP associa-
tion (Figure 1). Maximum elevations were observed within
24-48 h after MTX administration. The intensity of the
renal abnormality was significantly related to the dose, and
was not influenced by prolonged exposure to KP after MTX
administration. Figure 2 shows the reversibility of the pheno-
menon and the normalisation of these biological markers
between days 6 and 9 after MTX administration. Blood
levels of Na, K, Cl were identical in all experimental condi-
tions.
Analysis of the biological markers of haematopoietic and
hepatic functions revealed no evidence of modification of any
of them during any of the study conditions.
Figure 3a reveals that pretreatment by KP induced a
significant (approx. 70%) reduction in urinary excretion of
6-keto-PGFI,. This reduction was not enhanced by prolong-
ing treatment by KP. MTX alone did not affect the urinary
levels of 6-keto-PGFI,. Here again, urinary levels of 6-keto-
PGFIr. returned to the normal control range 4-11 days after
the end of KP treatment (Figure 3b).
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Figure 1 Histogram for the mean maximal values of the bio-
logical parameters of the renal function (five animals). For the
MTX dose of 50 mg kg-' (50) maximal values were recorded 24 h
after MTX dosing and for 100mg kg-' (100), 48 h after MTX
dosing. For controls (three animals), mean maximal values were
recorded after a single NaCI i.v. bolus; NaCl means animals
pretreated with NaCI only and KP means animals pretreated with
KP; A means sequence A; B means sequence B. *Statistically
significant from the individual reference value before any treat-
ment (P<0.05, t test of paired samples).
Pharmacokinetic parameters (Figures 4 and 5, Table I)
MTX was rapidly converted into its main circulating meta-
bolite, 7-OH-MTX. One to two hours after MTX administra-
tion, the blood concentrations of the metabolite were higher
than those of the parent drug.
At the MTX dose of 50 mg kg-', the elimination slope was
higher in the presence of prolonged treatment by KP
(sequence B) than when KP was stopped the day of MTX
(sequence A) dosing. The volume of distribution was also
increased in the presence of KP.
Table I Pharmacokinetic parameters
Treatment delivered
NaCI Kp Kp
Parameter (controls) (sequence A) (sequence B)
AUC MTX MTX 50 mg kg-' 374.2± 100.9 415.5± 135 365± 50.4
OLmol h 1-') MTX 100 mg kg-' 775± 53.5 1021 ±228.2a 1482± 728.2a
AUC 7-OH-MTX MTX 50 mg kg-' 450± 199.9 450.1± 124.7 490.8± 181.8
(jLmol h I-) MTX 100 mgkg-' 765.8± 180.6 2425.2± 1834.8a 2129.2± 1561.4a
AUC 7-OH-MTX/ MTX 50 mg kg-' 1.33 ±0.93 1.13±0.27 1.41 ±0.69
AUC MTX MTX 100mgkg-' 0.98±0.20 2.61±2.52c 1.34±0.29c
tl/2 P MTX(h) MTX 50mg kg-' n.e. 8.5± 3.5 19.9±9.2b
MTX 100mg kg-' 6.4±2.0 25.5±18.6c 28.5±34.1c
t1/2 P 7-OH-MTX(h) MTX 50 mgkg-' 10.4±2.4 17.5±11.3 22.6±11.4
MTX 100 mgkg-' 32.3± 11.9 48.1±8.1 67.3±75.9
CITB MTX 50 mgkg-' 5.17± 1.66 4.88±2.05 5.16±0.85
(ml min-' kg-') MTX 100 mg kg-' 4.66±0.26 3.70±0.95c 2.88±L.16c
CIR (ml min-' kg-') MTX 50 mg kg-' n.a. 1.48±0.22 2.04±0.87
MTX 100mg kg-' 2.29±0.15 1.03±0.65c 0.99±0.49c
Vdss (I kg-') MTX 50 mg kg-' 1.1±1.8 2.9± 1.3c 8.5± 5.4a,c
MTX 100mg kg-' 2.7±0.8 4.3±3.3c 4.6±3.0c
fu (%) MTX 50mg kg-' 42.6d 40±10.4 43.8± 15.8
(40.4, 44.8)
MTX 100mgkg-' 50.4±2.9 26.1±7.9c 36.7±3.0c
aStatistically significant(P<0.05) ascompared to controls.bStatistically significant (P<0.05)
between sequenceAand sequence B.cStatistically significant (P<0.05) between sequence Aplus
sequence B as compared to controls. dMean oftwo values given in brackets. n.e., not evaluable
(mostofthebloodconcentration levelsbelowthelimitofsensitivity,2 x 1O-8M). n.a., plasmaand
urines samples not conjointly available. For the definition ofpharmacokinetic parameters, see
Material and methods.
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Figure 2 Time-concentration profile of the biological para-
meters of the renal function during the observation period (five
animals treated by MTX plus KP sequence B). Mean values with
bars showing the standard deviation.
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Figure 4 Concentration-time profiles of mean blood concentra-
tions of MTX. Vertical bars indicate±standard deviation. a,
MTX dose of 50mg kg-'; b, MTX dose of 100mg kg-'. Squares,
controls; points, MTX plus KB sequence A; crosses, MTX plus
KP sequence B.
Is | I i PA At the MTX dose of 100mgkg-', the presence of KP
2 3 4 (sequences A and B taken together) significantly increased
the volume of distribution and reduced MTX total body
clearance, MTX renal clearance and the fraction of MTX
b eliminated as unchanged drug in urines as compared to
20 controls; the AUC4-,0 for MTX and 7-OH-MTX were also
significantly increased. When MTX was associated with KP,
the t,12 for 7-OH-MTX was prolonged by the MTX dose
increment and total body MTX clearance was reduced.
Table II gives the mean percentages of bound plasma
MTX 2 and 6 h after MTX administration in animals treated
by MTX only or by MTX plus KP. A reduction in bound
10 MIX was noted when KP was given with MTX; this reduc-
tion was more marked at 6 h than at 2 h after MTX adminis-
tration. Table III gives the results of the binding study in
5 vitro. The data indicate that not only MTX but also 7-OH-
MTX may be displaced from plasmatic binding sites by KP.
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Figure 3 a, Histogram for the urinary excretion of the prosta-
glandin 6-keto-PGF,, (mean values with vertical bars showing the
standard deviation, n = 3 animals). Open bars, controls with
NaCI; hatched bars, 8 days with KP (3 mg kg-' day-'); filled
bars, 11 days with KP (3 mg kg-'day-'). I =before treatment;
2 = after 7 days of i.p. treatment; 3 = I day after MTX 100 mg
kg-'; 4 = 3 days after MTX 100 mg kg-'; 5 = 14 days after MTX
100 mg kg-'. b, Evolution of amount of 6-keto-PGF1, excreted in
urines during the observation period (mean values with vertical
bars showing the standard deviation, n = 3 animals). Open
diamonds = MTX 100 mg kg-'; filled diamonds = MTX 100 mg
kg-' plus KP sequence B. MTX was given at the time 0.
Discussion
This study was designed to elucidate the origin of the drug
interaction between MTX and KP that can have fatal conse-
quences for patients (Thyss et al., 1986). Our initial observa-
tion suggested that renal toxicity was one of the major causes
of subsequent overexposure to MTX and ensuing toxicity.
However, it was not clear in these cases whether MTX itself
(Condit et al., 1969) or KP (Sennesael et al., 1986; Adams et
al., 1986) could induce such renal failure when given alone.
The present report clearly demonstrates that neither MTX
nor KP modified the biological parameters related to renal
function. By contrast, concomitant use of the two drugs
produced dramatic and reversible increases in blood urea and
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Figure 5 Concentration-time profiles of mean blood concentra-
tions of 7-OH-MTX. Vertical bars indicate ±standard deviation.
a, MTX dose of 50mgkg-'; b, MTX dose of 100mgkg-'.
Squares, controls; points, MTX plus KP sequence A; crosses,
MTX plus KP sequence B.
Table II Analysis of the plasmatic binding of MTX in vivo
MTX boundfraction in plasma
(%, mean±s.d.)
Time (h) Controls
after MTX (MTX only MTX+ KP Statistical
administration n = 3) (n = 9) analysis
2 55+6.4 44.3± 10.9 n.s.
6 62.2±11.9 41.1±10.9 P<0.05
MTX was given at thedose of100 mg kg-'. KPwas given at thedose
of 3 mg kg-' day-', during 8 days and stopped the day of MTX
injection.
creatinine. Although several pharmacokinetic abnormalities
were recently encountered when low dose MTX and NSAIDs
were associated for treatment of rheumatoid arthritis, there
was no evidence of MTX-related toxicity (Ahern et al., 1988).
This contrasted with earlier reports of fatal consequences
after an association of low dose MTX plus NSAIDs (Singh
et al., 1986; Daly et al., 1986). The present study clearly
reveals the role of the MTX dose in the intensity of renal
toxicity when combined with KP, with the lowest dose
(50mgkg-') causing a lesser elevation in blood urea and
creatinine.
These results also highlight the pharmacokinetic abnor-
malities induced by this drug association. The MTX dose had
an influence on pharmacokinetic alterations: at 50mgkg-1,
only the elimination half-life was significantly prolonged by
pretreatment with KP; at 100 mg kg-' more convincing
modifications were seen; both total body clearance and renal
clearance of MTX were significantly reduced. Interestingly,
the fraction of the MTX dose excreted as unchanged drug in
urines was reduced, indicating that KP pretreatment affected
the absolute recovery of MTX from urine. It is noteworthy
that neither renal nor pharmacokinetic abnormalities were
influenced by prolonging KP treatment after MTX admin-
istration. This indicates that the major cause of interaction is
the pretreatment phase by KP. This could have important
clinical implications: just stopping KP (or other NSAIDs) the
day of the anti-metabolite administration might not be
enough to avoid severe toxicity. Analysis of renal excretion
of 6-keto-PGFI, illustrates this situation. This prostaglandin
was selected because it is the stable metabolite of PGI2
(Schlondorff & Ardaillou, 1986), mainly synthesised by the
kidney (Patrono et al., 1982), and because prostacyclins play
a determinant role in renal blood flow regulation (Dunn,
1987). Predictably (Carmichael & Shankel, 1985), pretreat-
ment by KP significantly reduced renal excretion of 6-keto-
PGF,C. As MTX is mainly cleared by glomerular filtration
(Huang et al., 1979), pretreatment by KP quite logically
impairs renal elimination of the anti-metabolite. The origin
of the associated renal toxicity, reflected by the elevation of
blood urea and creatinine, is less clear. Prostaglandins affect
water metabolism in the kidney (Henrich, 1984); effects in-
clude antagonism of hydrosmotic activity, inhibition of active
chloride transport by the medullary thick ascending limb,
and regulation of medullary blood flow. As these three sites
are critical for renal production of a dilute urine, intratubular
precipitation of MTX or 7-OH-MTX might induce toxic
shock in the kidney, further impairing MTX elimination
because of reduced glomerular filtration. KP is mainly
eliminated in urine as a glucoronide metabolite (Populaire et
al., 1973). Thus, direct competition between KP and MTX at
the level of weak acid tubular secretion is another possibility
because such competition has been shown between MTX and
8 NSAIDs in rabbit kidney slices, although not with KP
(Nierenberg, 1983).
Table III Separate analysis ofthe plasmatic binding of MXT and 7-OH-MTX in vitro
Each experimental condition was done in triplicate
Controls With 2 h pre-incubation by KP Without pre-incubation by KP
(n = 3) (n = 3) (n = 3)
KP(moll') 0 2 x 10-4 2 x 10-5 2 x 10-6 2 x 10-4 2x 0-5 2x 10-6
Bound
fraction (%),
(mean±s.d.)
MTX 70.1± 1.6 54.1±2.6 65± 1.8 65.6±1 63.2±3 66.7± 1.3 67.1± 1.5
7-OH-MTX 82.4± 1 77.6±0.6 76.5± 2.1 78.9±2.2 82.5± 1.4 78.3± 3.8 80± 3.9
Effect of the concentration of KP on the binding of MTX or 7-OH-MTX (samples
pre-incubated andnonpre-incubated byKPtakentogether); forMTX: P<0.05(Kruskal
Wallis test); for 7-OH-MTX: n.s. (Kruskal Wallis test).
Effect ofthepre-incubation by KP on thebinding ofMTX or 7-OH-MTX ascompared
to the samples not pre-incubated by KP (all concentrations ofKP pooled); for MTX: n.s.
(Mann-Whitney test); for 7-OH-MTX: n.s. (Mann-Whitney test).
Effect ofthe presence ofKP on the binding ofMTX (samples pre-incubated and non
pre-incubated by KP compared to controls); for MTX: P<0.01 (Mann-Whitney test);
for 7-OH-MTX: P<0.05 (Mann-Whitney test).INTERACTION BETWEEN METHOTREXATE AND KETOPROFEN 741
Owing to the moderate MTX binding (Paxton, 1981) and
extensive KP binding (Kantor, 1986) to plasma proteins,
MTX binding was analysed in the presence of KP. A signi-
ficant reduction in bound MTX was observed in samples
taken 6 h after MTX administration in KP-pretreated
animals compared to controls. This could be explained by at
least two factors: first, by direct competition between MTX
and KP as indicated by the present in vitro data and next, by
the displacement of MTX induced by the elevated blood
levels of 7-OH-MTX as it has been shown that 7-OH-MTX
is a potent competitor for MTX protein binding (Lopez et
al., 1986). As a consequence of this higher MTX-free frac-
tion, a significant increase in the MTX volume ofdistribution
was noted in the presence of KP thus leading to tissue MTX
overexposure which increases the potential risk of MTX
toxicity.
Surprisingly, although the drug interaction was associated
with a significant drug overexposure in this study, there was
no haematological toxicity as observed clinically (Thyss et
al., 1986). This may be due to the extensive biotransforma-
tion of MTX into 7-OH-MTX in the rabbit (Sasaki et al.,
1983), as confirmed in the present study. Although 7-OH-
MTX is an active metabolite (Fabre et al., 1986), a more
recent study concluded that cell growth is only weakly inhib-
ited in the presence of 7-OH-MTX as compared to MTX
(Seither et al., 1989). The preponderance of biotransforma-
tion into 7-OH-MTX could have resulted in an overall reduc-
tion in drug activity in our study.
In conclusion, the present study reveals the existence of an
interaction between MTX and KP and demonstrates its renal
origin. Because inhibition of renal prostaglandin synthesis
appears to be a key factor, combination of MTX with all
types of NSAIDs should be considered with caution. Mere
stopping of NSAIDs the day before administration of MTX
may be insufficient to eliminate the high risk of drug inter-
action.
This work was supported by a grant from ARC. Parts of the work
were presented at the 1989 AACR meeting.
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